Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) has the poorest prognosis among the three major subtypes of breast cancer, and more than one-third of patients with TNBC experience recurrence or distant metastasis. Despite advances in diverse immunotherapy strategies for metastatic TNBC (mTNBC), multiple mechanisms underlying resistance to treatment remain unknown.

Methods

In this study, the dynamic changes in the immune landscape in mTNBC were assessed and compared with healthy donors using single-cell RNA sequencing (scRNA-seq) analysis. By integrating internal and public scRNA-seq data, 61,149 cells extracted from East Asian patients with mTNBC and 51,448 cells extracted from East Asian healthy donors were used to landscape a comprehensive cellular profile of mTNBC.

Res

SUBMITTER: Ju HY 

PROVIDER: S-EPMC12542204 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature